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Abstract: Alzheimer’s disease (AD) is one of the common causes of dementia. Despite several dec-
ades of serious research in AD there is no standard disease modifying therapy available. Stem cells 
hold immense potential to regenerate tissue systems and are studied in a number of brain-related dis-
orders. For various untreatable neurodegenerative disorders, such as Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) (current-approved drugs provide only symptomatic re-
lief), stem cell therapy holds a great promise and provides a great research opportunity. Here we review several stem cell 
transplantation studies with reference to both preclinical and clinical approaches. We focus on different sources of stem 
cells in a number of animal models and on molecular mechanisms involved in possible treatment of neurodegenerative 
disorders. The clinical studies reviewed suggest safety efficacy and translational potential of stem cell therapy. The thera-
peutic outcome of stem cell transplantation has been promising in many studies but no unifying hypothesis exists for an 
underlying mechanism. Some studies reported paracrine effects exerted by these cells via release of neurotrophic factors, 
while other studies reported immunomodulatory effects by transplanted cells. There are also reports supporting stem cell 
transplantation causing endogenous cell proliferation or replacement of diseased cells at the site of degeneration. In ani-
mal models of AD, stem cell transplantation is also believed to increase expression of synaptic proteins. A number of stem 
cell transplantation studies point out great potential for this novel approach in preventing or halting several neurodegen-
erative diseases. The current challenge is to clearly define the molecular mechanism by which stem cells operate and the 
extent of actual contribution by the exogenous and/or endogenous cells in the rescue of disease. 
Keywords: Stem cells, Alzheimer’s disease, neurodegeneration, synaptogenesis, differentiation, proliferation, therapeutics, 
transplantation. 
INTRODUCTION: THE POTENTIAL OF STEM CELL 
IMPLANTATION IN ALZHEIMER’S DISEASE 
A number of neurodegenerative disorders, such as Alz-
heimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) 
and Parkinson’s disease (PD) are untreatable, and they pro-
gressively worsen with age, resulting in death. The world 
Alzheimer Repot 2015 reported over 46 million individuals 
in the world’s population suffer from dementia, and this 
number is estimated to increase upto 131.5 million by 2050 
[1]. Dementia is associated with multiple causes that include 
alcoholism, AD, stroke, PD and drug/medication intoxica-
tion. It is the fifth leading cause of death in the US with age 
of 65 years or above. In 2015 AD prevalence in USA was 
estimated to be close to 5.3 million, and this is expected to 
rise up to 11 to 16 million in 2050 [2]. In India, the number 
of individuals which are suffering from AD and other de-
mentia is estimated to be approximate 3.7 million and this 
number is expected to double by the year 2030 [3]. 
*Address correspondence to this author at the Neuroscience Research Lab,
Department of Neurology, Post Graduate Institute of Medical Education and 
Research, Chandigarh, India; Tel: +91 9914209090;  
E-mail: akshay1anand@rediffmail.com 
The most common form of dementia, Alzheimer’s dis-
ease, is characterized by different stages of cognitive and 
functional impairment. Patients suffering from AD lose 
autonomy in their daily normal activities, and this progres-
sively deteriorates with age. In 1901, Alois Alzheimer, a 
German psychiatrist, diagnosed a 51 year-old woman with a 
condition he called “amnestic writing disorder” [4]. Her psy-
chosocial abnormalities included aphasia and memory im-
pairment. Later, in 1910 when Alzheimer’s supervisor pub-
lished his book Psychiatrie, he reported this case and men-
tioned this condition as Alzheimer’s disease (AD) [4]. Since 
then, extensive research has progressed worldwide to under-
stand several aspects of the disease, ranging from its pathol-
ogy, disease onset, prevalence, diagnosis and treatment in 
various cellular, pre-clinical and clinical studies. Currently, 
AD pathophysiology is based on several important hypothe-
ses i.e., including the cholinergic hypothesis, protein mis-
folding, and amyloid cascade hypotheses [5-7]. 
The hippocampus plays a significant role in memory en-
coding and retrieval. Hippocampus is the first region of the 
brain to be affected in AD. Injury to brain tissue has not been 
seriously considered for treatment by cell replacement 
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strategies as compared to the other organs e.g. skin and liver 
tissues. Earlier, neuroanatomists considered that the nervous 
system is incapable of regeneration. In 1962 Joseph Altman 
provided the first evidence of neurogenesis in the cerebral 
cortex and later, in 1963 he showed the occurrence of neuro-
genesis in the dentate gyrus of rat and cat hippocampus [8]. 
In some animals, neuronal precursors originate from the 
subventricular zone (SVZ) to the main olfactory bulb via 
specialized migratory route known as the rostral migratory 
stream (RMS). More recently, various strategies are being 
employed to activate these lesser population of stem cells by 
various methods [9]. Currently available FDA-approved 
drugs for AD provide symptomatic relief to the patients 
without alleviating elusive disease pathology. , Alternative 
strategies such as herbal remedies [10-12] and cell based 
therapies [13, 14] are being tested in preclinical settings with 
the hope of halting disease progression. The underlying 
mechanism is either replacement of degenerating neurons or 
exerting neuroprotection by the paracrine effect of trans-
planted cells by the secretion of neurotrophic factors (Fig. 1) 
[15]. The efficacy of stem cells has been studied in various 
pre-clinical studies by transplanting these cells into the dis-
ease-specific animal models. However, there is a gap of 
knowledge describing the underlying molecular mechanisms 
involved in the rescue of disease by transplanted cells. 
PATHOPHYSIOLOGICAL FEATURES IN ALZ-
HEIMER’S DISEASE  
Several animal studies and human brain biopsies have 
revealed the pathological hallmarks of AD, including ex-
tracellular amyloid-β (Aβ) plaque deposits and formation of 
intracellular neurofibrillary tangles (NFT). NFT are mis-
folded structures produced by aberrant phosphorylation of 
microtubule-stabilizing tau proteins. The process of Aβ for-
mation is known to play a significant role in AD etiology 
[16]. Amyloid plaques trigger a pathological cascade result-
ing in neurofibrillary tangles and neuroinflammation causing 
neuritic dysfunction, which ultimately leads to neuronal 
death. In AD patients, excessive accumulation of Amyloid 
plaques is likely to be due to dysregulation of activity of β-
site Amyloid Precursor Protein-Cleaving Enzyme 1 
(BACE1). BACE1 gives rise to Aβ from the membrane-
spanning Aβ precursor protein (APP). This is the rate limit-
ing step of Aβ production. This cleavage occurs at the APP 
N-terminus to form soluble APPβ, and the c-terminus is fur-
ther cleaved by γ-secretase complex, which yields Aβ40/42 
[17]. These Aβ fragments thus generated aggregate to form 
amyloid fibrils. Aβ40 (with 40 amino acid residue) is the 
predominant form but Aβ42 (with 42 residues) is more fibril-
logenic than its shorter sibling and is involved in disease 
pathology.  
 
Fig. (1). Outline for underlying mechanism in stem cell mediated reversal of AD pathology. Some underlying hypothesis may explain 
functional improvements in subjects of stem cell transplantation in AD. However, current experiments point to four possible explanations. A) 
Paracrine effects from release of neurotrophic factors by transplanted cells. B) Immunomodulatory effects by transplanted cells. C) Replace-
ment of diseased cells by transplanted cells. D) Proliferation of endogenous cells. It is likely that all four processes operate in interaction to 
produce any final salutary effects. 
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There are several environmental factors that cause epige-
netic changes in healthy individuals. It plays a significant 
role in regulating the gene expression through direct modifi-
cation of DNA and histone protein modification leading to 
genetic dysregulation thereby causing various disease pa-
thologies. In AD, amyloid fibril-induced neuroinflammation 
is believed to increase expression of epigenetic factors such 
as. methyl-CpG-binding protein 2 and histone Deacetylase 2 
and their interaction further suppresses the expression of 
synaptic protein leading to amyloid induced memory defi-
ciency [18].  
Tau is an intracellular microtubule associated protein that 
plays an essential role in microtubule stabilization. Abnor-
mal phosphorylation of tau leads to microtubule disruption. 
The formation of neurofibrillary tangles may be triggered by 
amyloid plaque. Likewise, another cholinergic hypothesis 
postulates a reduction in neurotransmitter acetylcholine in 
the AD patients [19] as the primary cause of AD. Besides 
amyloid plaque deposition and neurofibrillary tangle forma-
tion, vascular dysfunction also appears in AD pathophysiol-
ogy. 
Both genetic and environmental factors contribute to eti-
ology of AD. Genetic factors linked to autosomal dominant 
inherited mutations include presenilin 1, presenilin 2, amy-
loid precursor protein and enzymes that are involved in amy-
loid processing such as BACE1. These genetic forms, also 
called familial AD (FAD) contribute marginally towards 
prevalence (no more than 5% of AD cases [20]), whereas 
most cases are sporadic, with an unknown cause. The E4 
variant of apoE is largely known as a major genetic risk fac-
tor for the late onset of AD [21]. Studies suggest that there 
are some interactions with amyloid to cause this dramatic 
effect [22]. Some studies also propose that sporadic cases are 
the result of various environmental and epigenetic factors 
which lead to an etiology based upon “Latent Early-life As-
sociated Regulation” (LEARn). LEARn describes effects 
resulting from exposure of stressors in early life e.g. nutri-
tional imbalance, toxic metals (such as lead) and other stres-
sors, which induce epigenetic alterations on disease associ-
ated gene chromatin or histones [23]. These changes remain 
latent as (de)methylation of promoter or chromatin modifica-
tions by (de)acetylation, (de)methylation and 
(de)phosphorylation. Upon one or more additional hits in the 
later life, expression of modified gene(s) alters sufficiently to 
induce pathology. 
CELL TYPE CONSIDERATIONS FOR DISEASE 
MODIFYING THERAPIES 
The requirement of a suitable cell type with particular 
characteristics for specific disease types is needed for proper 
and effective cell transplantation. Stem cells from several 
tissues such as bone marrow and umbilical cord blood are 
well characterized for their proliferation and differentiation 
properties and can be an optimum source for transplantation 
[24, 25]. Current strategies emphasize culturing of isolated 
cells in an optimum medium with suitable nutrient environ-
ment to obtain the desired disease phenotype. The microen-
vironment also provides suitable niche for selective expres-
sion of desirable markers to trigger these cells for a special-
ized cell type [26, 27]. Long-term culture and characteriza-
tion of primary neurons isolated from rodent and human fetal 
tissue is essential for undertaking comparative studies. 
Abundant tau and amyloid-β production in human brain cul-
tures provides a powerful cellular model for AD. In a recent 
study Ray et al provide a well-characterized methodology 
for fetal human primary brain cell culture, which is useful to 
test the therapeutic efficacy of drugs targeting AD [28]. Cul-
tures of induced pluripotent stem cell (iPSC) generated from 
fibroblasts of familial AD (FAD) patients with presenilin 1 
and presenilin 2 mutations were characterized after acquiring 
neuronal lineage [29]. Apart from increased Aβ42 expres-
sion, the iPSC model also showed variable drug response 
and alleviation of stress induced response by docosahex-
aenoic acid (DHA) treatment [30]. Likewise, RNA silencing 
has also been used in this cellular model. Therapeutic strate-
gies derived, therefrom focus on targeting production of Aβ 
by identifying key molecular regulators of BACE1 expres-
sion. The authors have also elucidated the role of human 
micro-RNA (miR)-339-5p which negatively modulates 
BACE1 in primary human brain cultures, and expression of 
miR-339-5p is reduced in AD patients [31]. 
PRE-CLINICAL STUDIES TO PROBE REGENERA-
TIVE POTENTIAL OF STEM CELLS 
At present, there are no consensus measures to accurately 
diagnose and monitor progression of AD [32]. This signifi-
cantly hinders effective treatments against AD. To study AD 
pathologies and its targets, different animal models of AD 
have been established and tested in preclinical settings. 
These model systems range from laboratory animals like 
zebrafish, murid rodents and nonhuman primates to model 
invertebrates such as Drosophila and C elegans. Among 
these, rats and mice are widely used, and their transgenic 
counterparts are the most-established system to evaluate dis-
ease pathophysiology as well as effective treatment strate-
gies. Several strategies have been adopted to establish AD 
like pathologies and induced memory impairment in these 
models [33]. These include predetermined brain injury, neu-
rotoxin induced cell loss in brain and intra-cerebroventricular 
injection of Aβ peptides [34].	  
Currently used treatments for AD includes blocking neu-
rotransmitter degradation, which provide temporary symp-
tomatic relief without alleviating the pathophysiological bur-
den of the disease. Therefore, alternative cell based studies 
for transplantation have been carried out in the belief that 
either these cells replace degenerating neurons or secrete 
trophic factors that provide a protective environment to the 
endogenous cells. Various neurotrophic factors are secreted 
by the cells to modulate the synaptic functioning in brain. In 
particular, BDNF is synthesized by neurons and highly ex-
pressed in cortex and hippocampus; these regions are crucial 
for learning and memory in brain [37]. 
The animal models associated with Aβ-induced memory 
loss have been widely studied in understanding pathophysi-
ology of AD and testing therapeutic efficacy of various drug 
targets. Prakash et al. use intracerebroventricular (ICV) in-
jection of Aβ to study the role of pioglitazone, a peroxisome 
proliferator-activated receptor-γ (PPAR-γ) agonist, on neu-
rotrophic factor BDNF in a rat model of AD with neuroin-
flammation. Aβ-injured animals showed significant impair-
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ment in memory as well as reduced levels of BDNF, which 
were reversed by administration of pioglitazone [38]. Tang 
et al. demonstrated fibrillar Aβ40 induced neurotoxicity in 
rat hippocampus, characterized by congo red plaques and 
degenerating neurons at the site of injection. This pathologi-
cal outcome was supported by impaired cognitive perform-
ance in the rats, tested in Morris water maze. Further, they 
have used this model to validate cell replacement efficacy of 
neural precursor cells derived from human embryonic stem 
cells. The neural precursor cells are partially differentiated, 
as these cells are more precisely committed to their lineage 
[39]. The transplanted cells were found to ameliorate Aβ-
induced cognitive impairment in these rats and further sur-
vived, integrated and differentiated into GFAP and NF-200 
positive neuronal cells after 16 weeks of transplantation [40]. 
Blurton-Jones et al. explored the role of neural stem cell 
transplantation in reversal of memory impairment. To study 
the effect of neural stem cells (NSCs) in AD pathology and 
cognitive functions, these cells were transplanted into aged 
triple transgenic mice that express mutant presenilin, tau and 
APP with aggressive Aβ load. Remarkably, transplanted 
NSCs were found to ameliorate loss in spatial learning and 
memory without altering Aβ and tau pathologies. Further, 
these cells increased synaptic density in diseased brain, 
which was assisted by BDNF. Loss of function studies have 
revealed that NSCs exert regenerative effects mediated by 
BDNF. It was further found that restoration of memory loss 
occurred when recombinant BDNF was additionally supple-
mented [15]. The same group recently reported that when 
these NSCs were genetically engineered to stably release the 
Aβ degrading enzyme neprilysin, they could augment synap-
tic plasticity as well as ameliorate underlying Aβ pathology 
in triple transgenic mice [41]. Ealier, Neuralstem, Inc. had 
announced the first data on neural stem cells transplantation 
studies in an animal model of AD. Their group reported that 
HK532: IGF1 (NSI-532.IGF) cells ameliorate spatial learn-
ing deficits and improved memory in AD mice. To generate 
human insulin-like growth factor 1 (IGF-1), a cortical neural 
stem cell line was engineered. IGF-1 cells also impart a 
wide-range of neuroprotective properties [42]. Notably, the 
cells, which were administered in the peri-hippocampal re-
gion showed survival up to ten weeks. Also, mice with stem 
cell transplantation performed better than did control mice at 
fourteen weeks after the surgery. It would be reasonable to 
conclude that such preliminary studies point toward a poten-
tially feasible therapeutic approach to treat AD in the future 
and that the therapeutic effect of stem cells upon transplanta-
tion into the brain is supported by a combination of ap-
proaches and largely mediated or at least significantly influ-
enced by paracrine effects. 
IMMUNOMODULATORY EFFECTS OF STEM 
CELLS TARGETING AD PATHOLOGY 
Reports also suggest that transplanted stem cells exerts 
some immunomodulatory response at the site of injury, lead-
ing to release of cytokines that further target the underlying 
AD pathology. Jin et al. highlighted the phenomenon of 
crosstalk between transplanted cells and endogenous neu-
roproliferative cells by the transplantation of neural precur-
sor cells (NPC) in focal cerebral ischemia of rat brain. In 
their earlier study they found reduced infarct volume and 
improved behavioral outcomes upon transplantation of NPC 
in middle cerebral artery occlusion model of rat. In a more 
recent study neurogenesis was shown by increase in BrdU 
labeling and expression of neuronal migration protein dou-
blecortin in the ipsilateral subventricular zone (SVZ) 
whereas not in contralateral SVZ or subgranular zone (SGZ) 
in young and aged rats [43]. In another study, authors have 
administered umbilical cord blood-derived mesenchymal 
stem cells (UCB-MSC) in double transgenic mice of PS1 
and APP that substantially ameliorated loss of spatial learn-
ing and memory by microglia activation. Further, the expres-
sion of Aβ peptide, hyperphosphorylation of tau and β-
secretase activity were reduced significantly. This neuropro-
tective effect by UCB-MSC involved modulation of neuroin-
flammation due to reduction in pro-inflammatory and in-
crease in anti-inflammatory cytokines, induced by microglia 
activation [44]. These findings suggest that UCB-MSC acts 
as a therapeutic agent to ameliorate decline in cognitive 
functions in AD model mice. 
Besides amyloid plaque deposition and neurofibrillary 
tangle formation, vascular dysfunction also contributes to the 
Alzheimer’s Disease pathophysiology. Vascular endothelial 
growth factor (VEGF) is also implicated in AD related neu-
rodegeneration. Therefore Garcia et al used the strategy of 
providing VEGF by transplantation of overexpressing bone 
marrow derived mesenchymal cells into the lateral ventricles 
of brain using stereotaxic surgery in double transgenic 
mouse model with APPSWE/PS1dE9 mutations [45]. Behav-
ioral and molecular parameters were assessed for vasculari-
zation and amyloid plaque deposition. Outcomes included 
reduced behavioral deficit and amyloid deposition besides 
inducing favored neovascularization. Yang et al. have used 
cell based approach and transplanted differentiated neuron 
like cells in APP/PS1 transgenic mice. They used human 
mesenchymal stem cells derived from Wharton’s jelly of 
umbilical cord and transdifferentiated into neuron-like cells 
(HUMSC-NCs) by tricyclodecan-9-yl-xanthogenate (D609). 
Transplantation of HUMSC-NCs in a transgenic APP/PS1 
mouse model significantly reduced Aβ load and improved 
cognitive functions via increase in microglial activation and 
expression of the neprilysin (NEP) and Aβ degrading en-
zymes insulin-degrading enzyme (IDE). Expression of pro-
inflammatory markers associated with the modulation of 
M2-like microglia (a type of microglia classified based on its 
mannose receptor and its activation by IL-4 cytokine [46]) 
activation was reduced whereas expression of anti-
inflammatory markers, such as interleukin-4 (IL4), was 
found to be increased [47]. Mesenchymal stem cells derived 
from bone marrow of male Sprague–Dawley rats were trans-
planted in female rats by tail vein injection [48]. BM-MSCs 
were found to increase expression of nestin andcholine 
acetyltransferase positive cells at the injured area in the 
brain. Notably, these cells displayed a reduction in amyloid 
plaques in hippocampus. 
Thus, bone marrow cells bring about their therapeutic ef-
fect by mechanisms involving anti-apoptotic activity, immu-
nomodulation, and neurogenic properties. Furthermore, neu-
rogenesis in the subgranular zone of dentate gyrus may act as 
an endogenous repair mechanism in AD via Wnt pathway in 
amyloid-related neurodegeneration associated with AD. 
Workers also investigated the role of mesenchymal stem 
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cells on hippocampal neurogenesis by co-culturing with the 
amyloid treated neural progenitor cells. Mesenchymal stem 
cells treatment to NPC significantly enhances the expression 
of GFAP, Ki67, HuD c, SOX2, and Nestin. Transplantation 
of these mesenchymal stem cells in Aβ-treated animals in-
creases BrdU and HuD double positive cells in hippocampus 
at 2 and 4 weeks as compared to control and Aβ-treated 
alone animals [49]. This shows that MSC administration 
caused hippocampal neurogenesis and increased differentia-
tion of NPC, which is modulated by Wnt pathway. This may 
provide and may provide a far better therapeutic approach 
for treating AD patients than what is offered by anticho-
linesterase drugs. Zhang et al realized that neural stem cell 
transplantation could provide a better approach for the thera-
peutic treatment of AD and hypothesized that the transplan-
tation of NSC would ameliorate cognitive impairment by 
increased expression of synaptic protein. Therefore, they 
isolated NSC from mouse embryo at embryonic day 14 and 
transplanted these in both hippocampi of APP/PS1 trans-
genic mice. Indeed, there was enhancement in cognitive 
functions analyzed by better spatial learning and memory 
after 8th weeks of transplantation as compared to the control 
group. Further, the expression of synaptophysin (SYN) and 
GAP-43 were found to be increased significantly. Hence, 
these results suggest that NPC induced cognitive improve-
ment possibly by formation of new neural circuits [50]. 
Studies have also been carried out to mobilize the quies-
cent bone marrow stem cell population into the peripheral 
blood by using stimulating factors. Prakash et al evaluated 
the effect of granulocyte colony stimulating factor (GCSF) in 
Aβ induced memory loss in male adult Wistar rats, and they 
found significant escalation in behavioral performance after 
GCSF elevated the progenitor population and CD34 positive 
cells in the brain affecting neurogenesis [51]. Shetty et al 
demonstrated the efficacy of mesenchymal stem cells 
(MSCs) derived from umbilical cord tissue in a Parkinson 
disease model [52]. They have studied the comparative 
therapeutic efficacy of MSCs from umbilical tissue and bone 
marrow as well as efficacy of undifferentiated versus differ-
entiated cells in their model and found better efficacy of dif-
ferentiated MSCs into dopaminergic phenotype when trans-
planted. As mesenchymal stem cells lack immunomodula-
tory activity, these cells provide a novel cellular approach to 
treat such neurological disorders. Several sources of stem 
cells in combination with multiple approaches tested in pre-
clinical AD models are further discussed in Table 1. 
POTENTIAL ADVERSE EFFECTS STEM CELL 
THERAPY 
Niche provides the regulatory molecules and suitable 
physicochemical environment to facilitate the cells to behave 
in a particular fashion [53]. These cells are exploited for 
therapeutic purposes, by isolating them from their niche 
which can pose some unexpected or undesirable outcomes 
such as tumorigenicity, which has a major concern. Very few 
studies have reported the potential adverse effect of these 
stem cells upon transplantation. In one of the study, authors 
evaluated the long term safety efficacy of 253G1-NSs (neu-
ral stem cells). The 253G1-NSs were transplanted to treat 
spinal cord injury (SCI) in SCID-NOD mice. These trans-
planted cells were found to have temporary improvement of 
motor function assessed by rota rod experiment for upto 47 
days of post transplantation; however, this was followed by 
gradual deterioration in motor functioning [54]. It has also 
been shown to be involved in enhanced proliferation of 
grafted cells and tumor formation. The proportion of nestin 
positive cells have been found to be increased from 47 days 
and 103 post-transplantation which suggests tumor formation 
in the long term by the grafted cells. In an 18-years old pa-
tient with spinal cord injury at T10-T11, an olfactory mu-
cosal cells were transplanted after three years This ledled to 
severe back pain and paraplegia after 8 years. Further imag-
ing revealed a mass formation of an intrame-
dullary spinal cord [55]. 
The Yamanaka study of induced pluripotent stem cells 
opens a big window for untreatable diseases [56] as well as 
for stem cell clinical trials; even though the use of iPSCs 
also carries a risk for tumors formation. As the generation of 
iPSCs involve retroviral transduction by the factors i.e. 
Oct3/4, Sox2, Klf4 and c-Myc [57]. The retroviral transduc-
tion of c-Myc is believe to increase a risk for tumorigenicity, 
hindering its clinical application. Further the approach has 
also shown elimination of the c-Myc factor for iPSC genera-
tion, which is relatively safer than the earlier approach. 
Therefore, an evaluation of safety efficacy of stem cells 
would provide us better therapeutic approach and its clinical 
application [58, 59]. 
THE PUTATIVE LINK OF BDNF AND CREB BE-
HIND STEM CELL MEDIATED REGENERATION 
In brain BDNF and CREB (cAMP response element-
binding protein) are believed to play a major role in complex 
memory formation, consolidation and retention [60-62]. It is 
also reported in both in-vivo and in-vitro studies that Aβ in-
duced toxicity leads to downregulation of BDNF and its ma-
jor regulatory molecule CREB. Hota et al studied the phos-
phorylation of CREB to investigate the molecular mecha-
nism of bacoside action, as its administration in hypobaric 
hypoxia induced in rat model, increased learning ability and 
ameliorated cognitive dysfunction [63]. Tota et al. investi-
gated the effect of angiotensin II on spatial memory and 
BDNF expression in Sprague-Dawley male rats. Spatial 
memory was found to be reduced when evaluated by Morris 
water maze after angiotensin ICV administration and no 
change was observed in BDNF expression [64]. In an in-
vitro study, Sharma et al have investigated the role of CREB 
binding protein (CREB-BP) in neuronal differentiation. 
Their deletion construct p-CREBBP were transfected into 
NT2 cells and expression profile for neuronal genes i.e. 
SHH, Wnt, Notch and their mutant counterparts were evalu-
ated. Defects in neuronal differentiation due to aberrant in-
teraction of CREB-BP with their transcriptional regulatory 
proteins were investigated by CHIP-PCR and co-
immunoprecipitation. Cells that are lacking in CREB, 
BROMO and HAT domains were found to show more pro-
liferation and less differentiation whereas cells expressing 
CREBBP showed less proliferation and more differentiation 
[65]. In 2009, Verma et al suggested the role of dichlorvos in 
memory impairment by muscarinic receptor induced signal 
transduction and phosphorylation of CREB. Dichlorvos be-
longs to the organophosphate compounds which are widely
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Table 1. Preclinical Alzheimer’s studies of stem cell transplantation  
No Type/ Source of stem 
cell used 
Time points Route of Administra-
tion of stem cells 
Results/Outcome Animal model used  References 
1. Neural stem cells - Intra-hippocampus Ameliorated loss in 
spatial memory and 
learning by BDNF 
Increase in synaptic 
density 
Triple transgenic mice 
(3xTg-AD) that express 
PS-1, tau and APP 
[15] 
2. Neural precursor cells Transplanted in 3 
months and 24 months 
old rats 
Cortical infarct cavity Highlighted the cross-
talk between trans-
planted and endogenous 
cells. 
Increased endogenous 
neurogenesis. 
Focal cerebral ischemia 
in rat model 
[43] 
3. Umbilical cord blood-
mesenchymal stem 
cells 
Transplanted at 29,31 
and 33 weeks of age; 
 MWM analysis at 33 
week, 4 days 
- Improvement in spatial 
learning and memory 
by the microglial acti-
vation. 
Reduced expression of 
Aβ 
Double transgenic mice 
of PS1 and APP 
[44] 
4. Transdifferentiated 
human Wharton’s jelly 
mesenchymal stem 
cells into neuron-like 
cells 
Three weeks after 
transplantation MWM 
was performed 
Bilateral hippocampus 
injection 
Improvement in cogni-
tive functions. 
Reduced Aβ load by 
increase in microglial 
activation, insulin-
degrading enzyme and 
neprilysin expression.  
AβPP/PS1 transgenic 
mice model 
[47] 
5. Mesenchymal stem 
cells 
End point analysis done 
at 2 and 4 weeks after 
MSC transplantation 
Intra-hippocampus Increased hippocampal 
neurogenesis. 
Differentiation of NPC 
by Wnt signaling path-
way. 
Amyloid β treated mice [49] 
6. Neural stem cell  End point analysis 
after 8 weeks of trans-
plantation 
Intra-hippocampus Increased expression of 
synaptic protein i.e. 
synaptophysin and 
GAP-43. 
Ameliorate cognitive 
impairment 
APP + PS1 transgenic 
(Tg) mice 
[50] 
7. Umbilical cord tissue 
derived Mesenchymal 
stem cell  
IHC done at at 6, 12 
and 24 weeks, and at 1 
year post-
transplantation 
Substantia nigra Studied efficacy of 
undifferentiated versus 
differentiated. 
Dopaminergic differen-
tiated MSCs showed 
better results. 
Parkinson Disease 
model 
[52] 
8. Mesenchymal stem cell SC transplanted after 2 
hrs of injury; 
Behavioural assessment 
has been done at 1, 3, 7, 
14, 21 and 28 day af-
ter TBI; 
IHC done after 72 hrs 
of TBI 
Intravenously Transplantation of 
MSCs showed immu-
nomodulatory effects. 
Proinflammatory cyto-
kines were reduced. 
Increased anti-
inflammatory cytokine 
expression. 
Trau-
matic brain injury mode
l 
[98] 
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(Table 1)…… 
No Type/ Source of stem 
cell used 
Time points Route of Administra-
tion of stem cells 
Results/Outcome Animal model used  References 
9. Bone marrow derived 
mesenchymal stem cell 
(BM-MSC) 
MWM at 2 weeks after 
the surgery 
Intra-hippocampus Senile plaques were 
reduced. 
Significant increased 
DeltaNp73 protein 
expression. 
Better performance in 
Morris water maze. 
APP/PS1 transgenic 
mice 
[99] 
10. Human olfactory bulb 
neural stem cells 
NSC transplanted after 
10 days of ibotenic acid 
administration. 
Intra-hippocampus Cells were engineered 
to express nerve growth 
factor. 
Enhanced cognitive 
abilities. 
 Ibotenic acid induced 
AD rat model 
[100] 
11. Neural stem cell NSC were transplanted 
in 12-months old mice; 
IHC performed 5 weeks 
post-transplantation 
- No impact on Aβ 
plaques. 
Transplanted cells 
showed chemotaxis 
towards the plques. 
APP/PS1 double trans-
genic AD mice 
[101] 
12. Placenta derived Mes-
enchymal stem cell 
 Intravenous in mouse 
tail 
Improved cognitive 
function. 
Prevent neuronal death 
Reduced inflammatory 
cytokines. 
Promoted neuronal cell 
differentiation 
Amyloid β1-42 peptide 
infused in mouse model 
[102] 
13. Mesenchymal stem cell Aβ administered at 6 
week of age; 
MSC transplanted on 
post-operative day 1. 
 Reduction in Aβ levels 
Enhanced induction of 
autophagosome 
Amyloid beta treated 
animal model 
[103] 
14. T-regulatory cells edu-
cated by UC-MSC 
6 months old mice were 
used; 
Behavior test per-
formed after 2 weeks of 
transplantation 
Intracardiac injection Reduced microglial 
activation and systemic 
inflammation. 
Ameliorate cognitive 
function 
Decreased Aβ plaques 
deposition 
Transgenic 
AβPPswe/PS1dE9 mice 
[104] 
15. Amniotic membrane 
derived Mesenchymal 
stem cell 
Pathological analysis 
done at 1 week post-
transplantation; 
Behavior analysis at 12 
weeks post-
transplantation 
Intravenous injection Reduced proinflamma-
tory and increased anti-
inflammatory cytoki-
nes. 
More activation of 
microglial cells. 
Improved spatial mem-
ory 
Tg2576 transgenic mice 
model of AD 
[105] 
14. Adipose derived stem 
cell 
MWM was performed 
3 months of stem cells 
injection 
Intravenous transplan-
tation 
No immune response 
Migrated to brain by 
crossing blood brain 
barrier 
Rescued memory defi-
ciency 
Upregulated VEGF and 
IL-10 expression 
Tg2576 mice model of 
AD 
[106] 
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(Table 1)…… 
No Type/ Source of stem 
cell used 
Time points Route of Administra-
tion of stem cells 
Results/Outcome Animal model used  References 
15. Bone marrow derived 
Mesenchymal stem cell 
End point analysis is 
upto 2 months 
Intra-cerebral injection Increased expression of 
dynamin 1 and syn-
apsin1 
Aβ plaque deposition 
reduces 
 - [107] 
16. Mesenchymal stem cell 
derived from umbilical 
cord blood 
Ten months old mice 
when stem cells were 
administered 
Bilateral intra-
hippocampal admini-
stration 
Induced endogenous 
neprilysin expression 
Reduced Aβ plaques 
APP/PS1 transgenic 
mice model 
[108] 
17. Epidermal Neural crest 
stem cell 
14 days after Aβ ad-
ministration stem cells 
were injected 
CA3 region of hippo-
campus 
Increased granule cells 
in hippocampus 
Transplanted cells 
expressed neuronal 
markers like GFAP 
Amyloid-β1-40 injected 
AD rat model 
[109] 
18. Bone marrow derived 
Mesenchymal stem cell 
Stem cell injection after 
4 months of AlCl3 in-
duced AD 
Tail vein injection Reduced amyloid 
plaque in hippocampus. 
Increased choline ac-
teyltransferase positive 
and nestin cells. 
AlCl3 induced AD 
female rat model 
[48] 
19. VEGF overexpressing 
Bone marrow derived 
Mesenchymal stem cell 
Cells were transplanted 
in 6, 9 and 12 months 
old animal 
Lateral ventricles of 
brain 
Reduction in behavioral 
deficiency 
Reduced amyloid 
plaque in hippocampus. 
Improved 
neovascularization 
Double transgenic 
mouse model with 
APPswe/PS1dE9 muta-
tions 
[45] 
20. Choline acetyltrans-
ferase expressing hu-
man NSC 
Learning and memory 
test were done at 2, 4, 
and 6 weeks after 
transplantation 
CA3 region in hippo-
campus 
Differentiated into 
neurons 
Migration of trans-
planted cells towards 
injured area  
AF64A-cholinotoxin 
induced learning deficit 
rat model  
[110] 
21 Umbilical cord blood 
cells 
Age of mice were 7 
month old 
Peripheral administra-
tion 
Immunomodulation 
Reduced vascular amy-
loid β deposits 
Tg2576 AD mouse 
model 
[111] 
 
used to as insecticide which may act as cholinesterase inhibi-
tor [66]. Low doses of dichlorvos impaired the signal trans-
duction linked to the adenylyl cyclase pathway and reduced 
CREB phosphorylation, leading to neurobehavioral impair-
ment [67]. 
Neurotrophic factors such as BDNF, NGF and GDNF, 
which have been earlier shown to rescue hypoxia induced 
ischemic rat brain upon intravenous transplantation of UCB 
cells, indicates an intrinsic role for neurotrophic factors, 
rather than direct differentiation, being significant in stem 
cell mediated recovery [68]. It is pertinent to note that the 
role of BDNF has been well described in AD literature. 
BDNF levels are decreased when compared to healthy con-
trols in the postmortem brains of AD patients [69-71]. Ma-
ture BDNF and its mRNA expression have also been shown 
to be confined to hippocampus and parietal cortex region of 
the brain [72-74]. BDNF is believed to exert neuroprotective 
effect in several neurodegenerative diseases. This may in-
clude pathologies characterized by Aβ-induced neuronal cell 
death. Several studies have shown the complete reversal of 
neuroprotective effects driven by BDNF in neuronal culture 
death induced by Aβ in specific and dose-dependent manner 
[75-80]. BDNF induced neuroprotective effect has shown 
incorporation of the Trkβ receptor [76]. Moreover, specific 
Aβ42 induced neuronal cell death has been shown to be re-
versed by BDNF, in addition to other neurotrophins like 
IGF-1, GDNF [75]. 
Since CREB is a DNA binding protein and acts as a tran-
scription factor for several genes, including c-fos, tyrosine 
hydroxylase, several neuronal peptides, and, importantly, 
neurotrophin BDNF, it is possible that an association exists 
between the role of BDNF expression and its regulation by 
CREB in rescuing learning and memory deficits [81, 82]. 
The function of CREB in the formation of spatial memory; 
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conversion of this memory into long term memory and in 
neuronal plasticity is well documented [83]. It is well known 
that gene expression has a major role in memory consolida-
tion as well as long term potentiation [83, 84]. These expres-
sion profiles are possibly activated through CREB and in-
volvement of Ca++, protein kinase A (PKA) and by the acti-
vation of cAMP, but need additional studies [85-87]. The 
activated PKA would phosphorylate CREB protein which 
further regulates gene expression of several proteins [86, 88, 
89]. Recently, Suzuki et al. have shown the effect of CREB 
on both short as well as long term memory. They have re-
ported the increase in long term memory (LTM) as well as 
long term potential in hippocampus CA1 region in gain-of 
function CREB mice in which mice express dominant active 
CREB protein. In addition they reported short term memory 
improvement in response to fear conditioning and spatial 
clues, which was related with enhanced BDNF levels in 
these mice. Therefore, up-regulation of BDNF and CREB 
expression may mutually trigger enhancement of LTM and 
STM, suggesting that CREB mediated BDNF expression 
plays intrinsic role in memory consolidation and retrieval. 
(Fig. 2) [90]. 
CLINICAL STUDIES FOR TREATING NEURODE-
GENERATIVE DISORDERS: 
Although a number of pre-clinical studies have been 
launched, very few clinical studies have been carried out so 
far. Venkataramana et al suggested the safety and effective-
ness of autologous bone-marrow derived mesenchymal stem 
cells when transplanted unilaterally in PD patients. Notably, 
no adverse effects of these stem cells were seen, paving the 
way for additional studies in future [91]. In 2012, human 
retinal stem cells were used to treat PD patients. Authors 
isolated human retinal stem cells from retinal pigmented 
epithelium tissue from post-mortem eyes and cultured in-
vitro to differentiate into dopaminergic neurons. These cells 
were then transplanted by stereotaxic operation into the post-
commissural putamen of 12 PD patients. Interestingly, PET 
analysis showed a trend of increased dopamine release dur-
ing the 6 month study [92]. In a current study of a phase I 
open-label clinical trial, authors evaluated the safety efficacy 
of intrathecal and intravenous transplantation of autologous 
bone marrow cells in children with cerebral palsy. Eighteen 
children with cerebral palsy who had transplantation were 
evaluated for motor and cognitive functions and MRI was 
done after the sixth month showing it was a safe procedure 
[93]. 
There are very few reports registered at 
www.clinicaltrials.gov of stem cells transplantation in AD 
patients, and their outcomes are largely unavailable. In 2011 
Medipost Co Ltd. completed an open level, phase I safety 
and efficacy trial on Korean AD patients, but they did not 
post their outcome measures. Human umbilical cord blood 
derived MSCs (UCB-MSCs) were transplanted in AD pa-
tients at two different doses (3 million and 6 million) and 
endpoint analysis was measured by ADAS-cog scoring, PET 
 
Fig. (2). Schematic showing the plausible mechanism behind stem cell mediated cognitive improvement in Alzheimer’s disease. We 
propose that the therapeutic effect of stem cells upon transplantation into the brain is largely mediated by the paracrine effects. The increase 
in neurotrophic factors, such as e BDNF, results in increased CREB phosphorylation which in turn activates the genes that regulate cognitive 
functions and memory by involving one or other phenomena, such as e neuroprotection, cell proliferation, differentiation, cell migration, 
synaptogenesis and neurogenesis. 
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imaging and Aβ and tau levels in CSF [94]. Another group in 
China is currently recruiting AD patients in phase I/II trial in 
a similar study design with 30 probable participants, where 
patients are intravenously administered with 20 million hu-
man UCB-MSCs [95]. Medipost Co Ltd. has recently started 
a double blinded, placebo controlled, phase I/IIa trial in Ko-
rea where patients with mild to moderate AD will be sub-
jected to repeated intraventricular administrations of UCB-
MSCs and will be evaluated 24 weeks after first dose of 
transplantation [96]. 
CONCLUSION 
Stem cells have promising translational significance, evi-
dent by emrging scientific data showing therapeutic benefits 
in several neurodegenerative disorders. The intrinsic path-
ways through which these cells exert their therapeutic effects 
still remain a challenge requiring thorough investigation. 
There are several studies describing the underlying pathways 
ranging from proliferation, differentiation, immunomodula-
tion to cell replacement and paracrine effects at the site of 
neurodegeneration. Pre-clinical studies have shown variable 
effects by using different types and sources of stem cells. 
Several studies explain this on the basis of paracrine effects 
either mediated by neurotrophic factors orendogenous cell 
proliferation. In animal models of AD, stem cell transplanta-
tion has been shown toincrease of synaptic protein marker 
expression. Transplantation of mesenchymal stem cells have 
shown decrease in Aβ load due to microglial expression and 
escalation of Aβ degrading enzymes. A combinatorial ap-
proach, wherein stem cells are tagged with neurotransmitters 
or Aβ modifying enzymes may exhibit a substantial thera-
peutic outcome in AD. There is also insufficient literature to 
explain the actual relative contributions of exogenous cells 
and endogenous cells towards rescue of function after stem 
cell transplantation. There is absence of comparative studies 
involving different sources and types of stem cells i.e. undif-
ferentiated versus differentiated cells in animal models of 
AD. Nevertheless, a few clinical studies have paved the way 
for clinical translation but such innovative treatments also 
carry substantial risk for tumor formation[55]. A thorough 
investigation is needed on the sources, types, stages, doses 
and routes of stem cell transplantation in AD model to vali-
date their optimum therapeutic outcome. Moreover, the dif-
ferent stages of AD progression and other related pathologies 
may play a critical role in the outcome of the cell transplan-
tation. Hence understanding the etiology of AD and its other 
pathologies is of paramount significance for successful clini-
cal translation of stem cell related therapies [97].  
LIST OF ABBREVIATIONS 
AD = Alzheimer’s disease 
APP = Aβ precursor protein 
Aβ = Amyloid Beta 
BACE1 = β-Site Amyloid Precursor Protein-Cleaving 
Enzyme 1 
BDNF = Brain derived neurotrophic growth factor 
BM-MSCs = Bone-marrow derived mesenchymal stem 
cells 
Brdu = Bromodeoxyuridine 
CHIP = Chromatin Immunoprecipitation 
CREB = cAMP response element-binding protein 
CREBBP = CREB binding protein 
DHA = Docosahexaenoic acid 
FAD = Familial Alzheimer’s Disease 
GCSF = Granulocyte colony stimulating factor 
GFAP = Glial fibrillary acidic protein 
ICV = Intracerebroventricular 
IDE = Insulin-degrading enzyme 
IHC = Immunohistochemistry iPSC-Induced 
pluripotent stem cells 
LTM = Long term memory 
MRI = Magnetic resonance imaging 
NEP = Neprilysin 
NFT = Neurofibrillary tangles 
NPC  = Neural precursor cells 
NPC = Neural progenitor cells 
NSC = Neural stem cells 
MWM = Morris water maze 
PD = Parkinson Disease 
PET = Positron emission tomography 
PPAR-γ = peroxisome proliferator-activated receptor-
γ 
PS1 = Presilin1 
RMS = Rostral migratory stream 
SC = Stem Cells 
STM = Short term memory 
SVZ = Subventricular zone 
SYN = Synaptophysin 
TBI = Traumatic Brain Injury 
UCB-MSC = Umbilical cord blood derived mesenchy-
mal stem cells 
VEGF = Vascular endothelial growth factor 
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